Comparing treatment strategies using a synthesized clinical trial: an analysis of late versus early use of trimethoprim-sulfamethoxazole for AIDS patients

被引:0
作者
Finkelstein, DM
Schoenfeld, DA
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Publ Hlth, MGH Biostat Ctr, Boston, MA 02114 USA
关键词
survival; progression; semi-Markov; AIDS;
D O I
10.1016/S0378-3758(00)00334-7
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
This paper applies methodology of Finkelstein and Schoenfeld [Stat. Med. 13 (1994) 1747.] to consider new treatment strategies in a synthetic clinical trial. The methodology is an approach for estimating survival functions as a composite of subdistributions defined by an auxiliary event which is intermediate to the failure. The subdistributions are usually calculated utilizing all subjects in a study, by taking into account the path determined by each individual's auxiliary event. However, the method can be used to get a composite estimate of failure from different subpopulations of patients. We utilize this application of the methodology to test a new treatment strategy, that changes therapy at later stages of disease, by combining subdistributions from different treatment arms of a clinical trial that was conducted to test therapies for prevention of pneumocystis carinii pneumonia. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:179 / 189
页数:11
相关论文
共 11 条
[1]   A RANDOMIZED TRIAL OF 3 ANTIPNEUMOCYSTIS AGENTS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BOZZETTE, SA ;
FINKELSTEIN, DM ;
SPECTOR, SA ;
FRAME, P ;
POWDERLY, WG ;
HE, WL ;
PHILLIPS, L ;
CRAVEN, D ;
VANDERHORST, C ;
FEINBERG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (11) :693-699
[2]   STATISTICAL ISSUES ARISING IN AIDS CLINICAL-TRIALS [J].
ELLENBERG, SS ;
FINKELSTEIN, DM ;
SCHOENFELD, DA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1992, 87 (418) :562-569
[3]  
Finkelstein, 1996, Mol Diagn, V1, P5, DOI 10.1016/S1084-8592(96)70018-8
[4]   ANALYZING SURVIVAL IN THE PRESENCE OF AN AUXILIARY VARIABLE [J].
FINKELSTEIN, DM ;
SCHOENFELD, DA .
STATISTICS IN MEDICINE, 1994, 13 (17) :1747-1754
[5]   Clinical and prophylactic trials with assured new treatment for those at greater risk .2. Examples [J].
Finkelstein, MO ;
Levin, B ;
Robbins, H .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) :696-705
[6]   SUPREMUM VERSIONS OF THE LOG-RANK AND GENERALIZED WILCOXON STATISTICS [J].
FLEMING, TR ;
HARRINGTON, DP ;
OSULLIVAN, M .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1987, 82 (397) :312-320
[7]   A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021 [J].
HARDY, WD ;
FEINBERG, J ;
FINKELSTEIN, DM ;
POWER, ME ;
HE, W ;
KACZKA, C ;
FRAME, PT ;
HOLMES, M ;
WASKIN, H ;
FASS, RJ ;
POWDERLY, WG ;
STEIGBIGEL, RT ;
ZUGER, A ;
HOLZMAN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) :1842-1848
[8]   Editorial: The promise of risk-based allocation trials in assessing new treatments [J].
Mosteller, F .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) :622-623
[9]  
ROBBINS H, 1991, BIOMETRIKA, V78, P349
[10]   ESTIMATING THE SUPERIORITY OF A DRUG TO A PLACEBO WHEN ALL AND ONLY THOSE PATIENTS AT RISK ARE TREATED WITH THE DRUG [J].
ROBBINS, H ;
ZHANG, CH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) :3003-3005